A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors

Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC)

(2017) J. J. Karakunnel et al.   JOURNAL OF CLINICAL ONCOLOGY

A Comprehensive Review of Spontaneous Pneumothorax Complicating Sarcoma

(2010) Jeffrey B. Hoag et al.   CHEST

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

(2010) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

(2009) Noboru Yamamoto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

(2009) Ursula A. Matulonis et al.   JOURNAL OF CLINICAL ONCOLOGY

Dual-Agent Molecular Targeting of the ErbB2 Receptor: Killing One Bird With Two Stones

(2008) Hal W. Hirte et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

(2008) Manuela Schmidinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

(2007) John M. Maris et al.   PEDIATRIC BLOOD & CANCER